ID   UKF-NB-3rVCR10
AC   CVCL_9905
AS   CVCL_9912
SY   UKF-NB-3 VCR; UKF-NB-3rVCR
DR   cancercelllines; CVCL_9905
DR   IARC_TP53; 26507
DR   Wikidata; Q54990359
RX   PubMed=16142320;
RX   PubMed=16151587;
RX   PubMed=17505515;
RX   PubMed=19147553;
RX   PubMed=22170099;
RX   PubMed=24466371;
RX   PubMed=25749379;
RX   PubMed=27517323;
RX   PubMed=27735941;
WW   https://www.wass-michaelislab.org/rccl.php
CC   Part of: Resistant Cancer Cell Line (RCCL) collection.
CC   Doubling time: 19 +- 2.1 hours (PubMed=16142320).
CC   Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Heterozygous (PubMed=16142320; PubMed=19147553; PubMed=22170099).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_9904 ! UKF-NB-3
SX   Female
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 20
//
RX   PubMed=16142320; DOI=10.3892/ijo.27.4.1029;
RA   Kotchetkov R., Hernaiz Driever P., Cinatl J., Michaelis M.,
RA   Karaskova J., Blaheta R.A., Squire J.A., von Deimling A., Moog J.,
RA   Cinatl J. Jr.;
RT   "Increased malignant behavior in neuroblastoma cells with acquired
RT   multi-drug resistance does not depend on P-gp expression.";
RL   Int. J. Oncol. 27:1029-1037(2005).
//
RX   PubMed=16151587;
RA   Bedrnicek J., Vicha A., Jarosova M., Holzerova M., Cinatl J. Jr.,
RA   Michaelis M., Cinatl J., Eckschlager T.;
RT   "Characterization of drug-resistant neuroblastoma cell lines by
RT   comparative genomic hybridization.";
RL   Neoplasma 52:415-419(2005).
//
RX   PubMed=17505515; DOI=10.1038/sj.bjc.6603777; PMCID=PMC2359931;
RA   Blaheta R.A., Michaelis M., Natsheh I., Hasenberg C., Weich E.,
RA   Relja B., Jonas D., Doerr H.-W., Cinatl J. Jr.;
RT   "Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant
RT   neuroblastoma tumour cells to endothelium.";
RL   Br. J. Cancer 96:1699-1706(2007).
//
RX   PubMed=19147553; DOI=10.1158/0008-5472.CAN-08-1856;
RA   Michaelis M., Rothweiler F., Klassert D., von Deimling A., Weber K.,
RA   Fehse B., Kammerer B., Doerr H.-W., Cinatl J. Jr.;
RT   "Reversal of P-glycoprotein-mediated multidrug resistance by the
RT   murine double minute 2 antagonist nutlin-3.";
RL   Cancer Res. 69:416-421(2009).
//
RX   PubMed=22170099; DOI=10.1038/cddis.2011.129; PMCID=PMC3252738;
RA   Michaelis M., Rothweiler F., Barth S., Cinatl J., van Rikxoort M.,
RA   Loschmann N., Voges Y., Breitling R., von Deimling A., Rodel F.,
RA   Weber K., Fehse B., Mack E., Stiewe T., Doerr H.-W., Speidel D.,
RA   Cinatl J. Jr.;
RT   "Adaptation of cancer cells from different entities to the MDM2
RT   inhibitor nutlin-3 results in the emergence of p53-mutated
RT   multi-drug-resistant cancer cells.";
RL   Cell Death Dis. 2:e243.1-e243.8(2011).
//
RX   PubMed=24466371; DOI=10.1593/tlo.13544; PMCID=PMC3890703;
RA   Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J.,
RA   Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A.,
RA   Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.;
RT   "Testing of SNS-032 in a panel of human neuroblastoma cell lines with
RT   acquired resistance to a broad range of drugs.";
RL   Transl. Oncol. 6:685-696(2013).
//
RX   PubMed=25749379; DOI=10.18632/oncotarget.2889; PMCID=PMC4627332;
RA   Michaelis M., Rothweiler F., Loschmann N., Sharifi M., Ghafourian T.,
RA   Cinatl J. Jr.;
RT   "Enzastaurin inhibits ABCB1-mediated drug efflux independently of
RT   effects on protein kinase C signalling and the cellular p53 status.";
RL   Oncotarget 6:17605-17620(2015).
//
RX   PubMed=27517323; DOI=10.18632/oncotarget.11160; PMCID=PMC5295411;
RA   Loschmann N., Michaelis M., Rothweiler F., Voges Y., Balonova B.,
RA   Blight B.A., Cinatl J. Jr.;
RT   "ABCB1 as predominant resistance mechanism in cells with acquired
RT   SNS-032 resistance.";
RL   Oncotarget 7:58051-58064(2016).
//
RX   PubMed=27735941; DOI=10.1038/cddis.2016.257; PMCID=PMC5133961;
RA   Voges Y., Michaelis M., Rothweiler F., Schaller T., Schneider C.,
RA   Politt K., Mernberger M., Nist A., Stiewe T., Wass M.N., Rodel F.,
RA   Cinatl J. Jr.;
RT   "Effects of YM155 on survivin levels and viability in neuroblastoma
RT   cells with acquired drug resistance.";
RL   Cell Death Dis. 7:e2410.1-e2410.11(2016).
//